CAS 944401-56-3 | BUPA-008 : Buparlisib
(World's Largest Pharmaceutical Supplier)
- CAS Number: 944401-56-3
- Stock: 999g
- Assay: 0.00%
CAS 944401-56-3, known as Palbociclib, is a breakthrough drug used in the treatment of advanced breast cancer. This small molecule inhibitor has revolutionized the field of oncology and offers hope to patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Palbociclib works by targeting cyclin-dependent kinases 4 and 6 (CDK4/6), enzymes that play a crucial role in cell cycle progression. By inhibiting CDK4/6, Palbociclib effectively slows down the growth of cancer cells, preventing them from dividing and proliferating.
CAS 944401-56-3, also known as Palbociclib, is a small molecule inhibitor that has revolutionized the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. This product has several noteworthy properties that make it a valuable therapeutic option in oncology.
Firstly, CAS 944401-56-3 targets cyclin-dependent kinases 4 and 6 (CDK4/6), enzymes involved in cell cycle regulation. By selectively inhibiting CDK4/6, Palbociclib blocks the progression of cancer cells from the G1 phase to the S phase, effectively slowing down their proliferation and growth.
Secondly, Palbociclib has shown impressive clinical efficacy when used in combination with hormonal therapies such as aromatase inhibitors. Clinical trials have demonstrated improved progression-free survival and overall response rates in postmenopausal women with HR+, HER2- advanced breast cancer when Palbociclib is added to standard hormone therapy regimens.